96. クローン病 [臨床試験数:2,209,薬物数:1,276(DrugBank:240),標的遺伝子数:166,標的パスウェイ数:210

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03221166February 27, 20185/7/2017Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic FactorsThalidomide, a Novel Immunological Treatment to Modify the Natural History of Paediatric Crohn's Disease: a New Proposal From a Well-established Paediatric Research NetworkCrohn DiseaseDrug: Thalidomide;Drug: InfliximabIRCCS Burlo GarofoloCentro di Riferimento Oncologico - Aviano;Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaTerminated6 Years17 YearsAll9Phase 3Italy
2EUCTR2016-000786-24-IT07/03/201730/11/2016Efficacy and safety of thalidomide in pediatric patients with Crohn's diseaseThalidomide, a novel immunological treatment to modify the natural history of paediatric Crohn's disease: a new proposal from a well-established paediatric research network - Talidomide in Crohn disease in Pediatrics Crohn's Disease
MedDRA version: 19.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
IRCCS Burlo GarofoloNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
124 Human pharmacology (Phase 1): no Therapeut1c exploratory (Phase 2): no Therapeut1c conf1rmatory - (Phase 3): yes Therapeut1c use (Phase 4): noItaly
3NCT02998827November 201624/11/2016Thalidomide Results in Diminished Ovarian Reserve in Reproductive Age Female IBD PatientsCrohn DiseaseDrug: Thalidomide;Drug: infliximab, azathioprine;Other: enteral nutritionSixth Affiliated Hospital, Sun Yat-sen UniversityNULLEnrolling by invitationN/AN/AFemale90N/ANULL
4NCT02956538October 201613/10/2016Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using ThalidomideInduced Adult Refractory Active Crohn's Disease Clinical Relieving by Using Thalidomide: A Randomized, Double-blind, Placebo-controlled Multicenter Clinical StudyCrohn DiseaseDrug: Thalidomide;Drug: placebo(for thalidomide)Sixth Affiliated Hospital, Sun Yat-sen UniversityNULLRecruiting18 Years50 YearsBoth72Phase 0China
5ChiCTR-OPC-160086552016-05-012016-06-16Efficacy and safety of thalidomide for patients with Crohn's Disease: a prospective multicenter observational study from ChinaEfficacy and safety of thalidomide for patients with Crohn's Disease: a prospective multicenter observational study from China Crohn‘s Disease1:Thalidomide 75-100mg qd;2:Thalidomide 150-200mg qd;3:Thalidomide 75-100mg qd+MTX 20-25mg /W;Peking Union Medical College HospitalNULLRecruiting1670Both1:90;2:90;3:90;China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT02501291January 201320/5/2015Thalidomide in Treating Crohn's DiseaseThalidomide in Inducing and Maintaining Remission of Crohn's DiseaseCrohn's DiseaseDrug: ThalidomideFirst Affiliated Hospital, Sun Yat-Sen UniversityNULLCompleted18 Years75 YearsBoth47Phase 2China
7NCT00720538August 200818/7/2008Thalidomide in Pediatric Inflammatory Bowel Diseases.Randomized Controlled Double-blind Vs. Placebo Multicentre Study on the Safety and Effectiveness of Thalidomide in the Treatment of Refractory Crohn's Disease and Ulcerative Colitis.Inflammatory Bowel Diseases;Crohn's Disease;Ulcerative ColitisDrug: Thalidomide;Drug: placeboIRCCS Burlo GarofoloOspedale Meyer;Pediatric Gastroenterology Unit, IRCCS Gaslini, Genoa.;Vittore Buzzi Children's Hospital;University of Pisa;Pediatric Gastroenterology Unit, University of Messina.;Università degli Studi di Brescia;University of TriesteCompleted2 Years18 YearsBoth84Phase 3Italy
8EUCTR2005-005414-20-IT06/03/200631/01/2006Randomized controlled double-blind Vs. placebo multicentre study on the safety and effectiveness of thalidomide in the treatment of refractory Crohn s disease and ulcerative colitis. - Thalidomide and IBDRandomized controlled double-blind Vs. placebo multicentre study on the safety and effectiveness of thalidomide in the treatment of refractory Crohn s disease and ulcerative colitis. - Thalidomide and IBD Inflammatory Bowel Disease Crohn Disease, Ulcerative Colitis
MedDRA version: 6.1Level: PTClassification code 10021972
Trade Name: Thalidomide Pharmion
INN or Proposed INN: Thalidomide
ISTITUTO PER L INFANZIA BURLO GAROFOLONULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
124Italy